Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.41 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 2/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phentydrone SCHEMBL875187 | 0.92 | MEN1 (0.57) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| Phentydrone SCHEMBL7556165 | 0.90 | MEN1 (0.39) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| Phentydrone SCHEMBL5213043 | 0.90 | CDC25B (0.39) | MEN1KMT2ACDC25BMAOAMAPT | |
| Anthraquinone SCHEMBL11352939 | 0.89 | MEN1 (0.60) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| SCHEMBL545308 | 0.87 | MEN1 (0.55) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| SCHEMBL29519720 | 0.87 | MEN1 (0.55) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| Phentydrone SCHEMBL9628384 | 0.86 | MEN1 (0.50) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| SCHEMBL10697306 | 0.85 | MEN1 (0.52) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| SCHEMBL29080974 | 0.85 | CDC25B (0.52) | MEN1KMT2ACDC25BIDO1DNMT1 | |
| SCHEMBL10697311 | 0.85 | MEN1 (0.52) | MEN1KMT2ACDC25BIDO1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE HOLDINGS CORPORATION | 2024-05-30 | — | — | US | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-11158820-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| EP-0995755-A1 | Prodrugs of Thrombin inhibitors | Astra Aktiebolag (SE) | 2000-04-26 | — | — | EP | disclosed |
| US-5965692-A | ANTICOAGULANTS FOR TREATMENT OF THROMOBOSIS AND HYPERCOAGULABILITY IN BLOOD AND TISSUES | ASTRA AB (SE) | 1999-10-12 | — | — | US | disclosed |
| US-5912352-A | CATALYTIC REDUCTION OF HYDRAZIDE TO HYDRAZINE DERIVATIVE IN PRESENCE OF COMPLEX HYDRIDE; ACYL MIGRATION; HYDROGENATION; CATALYST SELECTIVITY | NOVARTIS FINANCE CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| WO-1999014226-A2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| EP-0869966-A1 | PRODRUGS OF THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997046514-A1 | PROCESS FOR THE PREPARATION OF HYDRAZINE DERIVATIVES USEFUL AS INTERMEDIATES FOR THE PREPARATION OF PEPTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997023499-A1 | PRODRUGS OF THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-07-03 | — | — | WO | disclosed |
| US-4277601-A | Preparation of sodium cefuroxime | GLAXO GROUP LIMITED (GB) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | MEN1 1453/4885KMT2A 1071/4885CDC25B 393/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | MEN1 1453/4885KMT2A 1071/4885CDC25B 393/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | MEN1 3083/4885KMT2A 792/4885CDC25B 273/4885 |
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | MEN1 2921/4885KMT2A 4860/4885CDC25B 1566/4885 |
| US-11158820-B2 | Organic electroluminescent materials and devices | TPR, PIR, PPOX | MEN1 2090/4885KMT2A 3121/4885CDC25B 2287/4885 |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | MEN1 2921/4885KMT2A 4860/4885CDC25B 1566/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | MEN1 1955/4885KMT2A 271/4885CDC25B 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.